en

PRODUCT DETAIL

Mometasone furoate Cipla 50 mikrogramov nosový suspenzný sprej

Code 8832A
MA number 69/0039/14-S
Product Form: aer nau 1x18 g/140 dávok (fľ.HDPE s dávkovačom)
MA Status: D - Marketing Authorisation valid for an unlimited period
Type of procedure: Mutual recognition procedure
MAH, country: Cipla Europe NV , Belgium
Therapeutic Class: 69 - OTORHINOLARYNGOLOGICA
ATC:
R RESPIRATORY SYSTEM
R01 NASAL PREPARATIONS
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01AD Corticosteroids
R01AD09 Mometasone
Shelf life: 24
Container: bottle HDPE with dose dispenser
Route of admin.: Nasal use
Prescription Status: Medicinal product subject to medical prescription.
Legal basis: Article 10(3) hybrid application
MA issued: 29.01.2014
Pediatric indication: Yes
Pediatric posology: Yes
Pediatric warnings: Yes
SPC: SPC_Mometasone furoate Cipla_01/2025.pdf  
PIL: PIL_Mometasone furoate Cipla_03/2025.pdf  
Safety feature Yes
Data update: 21.02.2025
eu-flag.png sk-flag.png